Limited Pelvic Lymph Node Dissection Does Not Improve Biochemical Relapse-Free Survival at 10 Years After Radical Prostatectomy in Patients with Low-Risk Prostate Cancer

Urology

Volumn 71, Issue 1, 2008, Pages 141-145

  Weight, Christopher J ^a   Reuther, Alwyn M ^a   Gunn, Paul W ^a   Zippe, Craig R ^a   Dhar, Nivedita B ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 38649103775     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.08.027     Document Type: Article

References (24)

1. Allaf M.E., Palapattu G.S., Trock B.J., et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172 (2004) 1840-1844
2. Masterson T.A., Bianco Jr. F.J., Vickers A.J., et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175 (2006) 1320-1324
3. Roehl K.A., Han M., Ramos C.G., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910-914
4. Fowler Jr. J.E., and Whitmore Jr. W.F. The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer 47 (1981) 2941-2945
5. Crawford E.D., Batuello J.T., Snow P., et al. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma. Cancer 88 (2000) 2105-2109
6. Kawakami J., Meng M.V., Sadetsky N., et al. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol 176 (2006) 1382-1386
7. Bader P., Burkhard F.C., Markwalder R., et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. J Urol 168 (2002) 514-518
8. Bader P., Burkhard F.C., Markwalder R., et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy: is there a chance of cure?. J Urol 169 (2003) 849-854
9. Schumacher M.C., Burkhard F.C., Thalmann G.N., et al. Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/ml undergoing radical prostatectomy for prostate cancer?. Eur Urol 50 (2006) 272-279
10. Bhatta-Dhar N., Reuther A.M., Zippe C., et al. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 63 (2004) 528-531
11. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005-7012
12. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
13. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
14. Srinivas V., Morse M.J., Herr H.W., et al. Penile cancer: relation of extent of nodal metastasis to survival. J Urol 137 (1987) 880-882
15. Skinner D.G. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 128 (1982) 34-36
16. Clark T., Parekh D.J., Cookson M.S., et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169 (2003) 145-147
17. DiMarco D.S., Zincke H., Sebo T.J., et al. The extent of lymphadenectomy for pTxN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121-1125
18. Campbell S.C., Klein E.A., Levin H.S., et al. Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 46 (1995) 352-355
19. Berglund R.K., Sadetsky N., DuChane J., et al. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol 177 (2007) 526-529
20. Weckermann D., Wawroschek F., and Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?. Eur Urol 47 (2005) 45-50
21. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
22. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 (2002) 528-534
23. Joslyn S.A., and Konety B.R. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68 (2006) 121-125
24. Miyake H., Hara I., Kurahashi T., et al. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13 (2007) 1192-1197